JP6982716B2 - 複素環式化合物及びその使用 - Google Patents
複素環式化合物及びその使用 Download PDFInfo
- Publication number
- JP6982716B2 JP6982716B2 JP2019531279A JP2019531279A JP6982716B2 JP 6982716 B2 JP6982716 B2 JP 6982716B2 JP 2019531279 A JP2019531279 A JP 2019531279A JP 2019531279 A JP2019531279 A JP 2019531279A JP 6982716 B2 JP6982716 B2 JP 6982716B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- heterocycloalkyl
- heteroaryl
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 NCCCNC1C*CCC1 Chemical compound NCCCNC1C*CCC1 0.000 description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N C1CCNCC1 Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- FYKOQMOIMIXVKW-RXMQYKEDSA-N CC[C@@H](C)NOC Chemical compound CC[C@@H](C)NOC FYKOQMOIMIXVKW-RXMQYKEDSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762444601P | 2017-01-10 | 2017-01-10 | |
| US62/444,601 | 2017-01-10 | ||
| PCT/US2018/012748 WO2018132326A1 (en) | 2017-01-10 | 2018-01-08 | Heterocyclic compounds and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020506879A JP2020506879A (ja) | 2020-03-05 |
| JP2020506879A5 JP2020506879A5 (enExample) | 2021-01-14 |
| JP6982716B2 true JP6982716B2 (ja) | 2021-12-17 |
Family
ID=62839630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531279A Active JP6982716B2 (ja) | 2017-01-10 | 2018-01-08 | 複素環式化合物及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10882854B2 (enExample) |
| EP (1) | EP3568137A4 (enExample) |
| JP (1) | JP6982716B2 (enExample) |
| KR (1) | KR102335082B1 (enExample) |
| CN (1) | CN110381949B (enExample) |
| AU (1) | AU2018208366B2 (enExample) |
| CA (1) | CA3047146C (enExample) |
| RU (1) | RU2756055C2 (enExample) |
| TW (1) | TWI664174B (enExample) |
| WO (1) | WO2018132326A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110176278B (zh) * | 2019-05-24 | 2021-09-28 | 河海大学 | 氨基酸氯化生成二氯乙腈的连续反应动力学模型建模方法 |
| TWI818651B (zh) * | 2021-08-02 | 2023-10-11 | 財團法人國家衛生研究院 | 嘧啶化合物及其用途 |
| TW202345843A (zh) * | 2022-04-06 | 2023-12-01 | 財團法人國家衛生研究院 | 脂質奈米顆粒及脂質體 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274588B1 (en) * | 1999-05-31 | 2001-08-14 | Hoffmann-La Roche Inc. | 4-phenyl-pyrimidine derivatives |
| AU2003288994A1 (en) * | 2002-12-10 | 2004-06-30 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compounds and medicinal use thereof |
| US7456289B2 (en) | 2004-12-31 | 2008-11-25 | National Health Research Institutes | Anti-tumor compounds |
| JP5118029B2 (ja) | 2005-06-14 | 2013-01-16 | タイゲン バイオテクノロジー カンパニー，リミテッド | ピリミジン化合物 |
| US20070117858A1 (en) * | 2005-11-23 | 2007-05-24 | Mingde Xia | Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators |
| UY30444A1 (es) | 2006-06-30 | 2008-01-31 | Astrazeneca Ab | Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos. |
| CA2656290A1 (en) * | 2006-07-05 | 2008-01-10 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
| HUE025179T2 (en) | 2008-04-21 | 2016-02-29 | Taigen Biotechnology Co Ltd | Heterocyclic Compounds |
| CA2734486A1 (en) | 2008-08-20 | 2010-02-25 | Southern Research Institute | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| JP6615207B2 (ja) * | 2014-09-22 | 2019-12-04 | ユ−シェン チャオ | 複素環式化合物及びその使用 |
-
2018
- 2018-01-08 WO PCT/US2018/012748 patent/WO2018132326A1/en not_active Ceased
- 2018-01-08 KR KR1020197019661A patent/KR102335082B1/ko active Active
- 2018-01-08 US US15/864,707 patent/US10882854B2/en active Active
- 2018-01-08 CA CA3047146A patent/CA3047146C/en active Active
- 2018-01-08 EP EP18738907.7A patent/EP3568137A4/en active Pending
- 2018-01-08 CN CN201880005371.5A patent/CN110381949B/zh active Active
- 2018-01-08 AU AU2018208366A patent/AU2018208366B2/en active Active
- 2018-01-08 JP JP2019531279A patent/JP6982716B2/ja active Active
- 2018-01-08 RU RU2019124448A patent/RU2756055C2/ru active
- 2018-01-09 TW TW107100765A patent/TWI664174B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3047146C (en) | 2021-08-31 |
| RU2019124448A3 (enExample) | 2021-02-26 |
| RU2756055C2 (ru) | 2021-09-24 |
| US10882854B2 (en) | 2021-01-05 |
| KR20190104334A (ko) | 2019-09-09 |
| JP2020506879A (ja) | 2020-03-05 |
| BR112019013493A2 (pt) | 2020-01-07 |
| US20180208588A1 (en) | 2018-07-26 |
| TWI664174B (zh) | 2019-07-01 |
| CN110381949A (zh) | 2019-10-25 |
| EP3568137A1 (en) | 2019-11-20 |
| TW201831466A (zh) | 2018-09-01 |
| RU2019124448A (ru) | 2021-02-12 |
| CN110381949B (zh) | 2023-12-08 |
| AU2018208366B2 (en) | 2020-12-17 |
| CA3047146A1 (en) | 2018-07-19 |
| NZ754272A (en) | 2021-05-28 |
| WO2018132326A1 (en) | 2018-07-19 |
| EP3568137A4 (en) | 2020-05-27 |
| KR102335082B1 (ko) | 2021-12-06 |
| AU2018208366A1 (en) | 2019-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2768827C2 (ru) | Модуляторы хемокинового рецептора и их применение | |
| KR102083857B1 (ko) | 신규 치환된 인다졸, 그의 제조 방법, 상기 신규 치환된 인다졸을 함유하는 제약 제제, 및 약물을 제조하기 위한 상기 신규 치환된 인다졸의 용도 | |
| JP6313714B2 (ja) | 治療上活性な化合物およびそれらの使用方法 | |
| KR20120055571A (ko) | 종양성 또는 자가면역 질환 치료용 전구약물로서의 푸라자노벤즈이미다졸 | |
| JP6615207B2 (ja) | 複素環式化合物及びその使用 | |
| CN105246887B (zh) | 香豆素衍生物以及用于治疗过度增生性疾病的方法 | |
| JP7287952B2 (ja) | アデノシン受容体アンタゴニストとしてのベンズイミダゾール誘導体 | |
| KR20180137497A (ko) | N-｛6-(2-히드록시프로판-2-일)-2-[2-(메틸술포닐)에틸]-2h-인다졸-5-일｝-6-(트리플루오로메틸)피리딘-2-카르복스아미드의 다형체 형태 | |
| RU2765718C1 (ru) | Замещенное производное дигидропирролопиразола | |
| KR102782698B1 (ko) | 피롤로[1,2-b]피리다진 유도체 | |
| JP6982716B2 (ja) | 複素環式化合物及びその使用 | |
| CN110997657A (zh) | 咪唑烷化合物 | |
| JPH06503344A (ja) | 可溶性の補体受容体と、補体を抑制しかつ／または免疫活性を抑制する化合物との相乗組成物 | |
| JP7336434B2 (ja) | アデノシン受容体アンタゴニストとしてのチアゾロピリジン誘導体 | |
| CN104995179A (zh) | 作为hcv抗病毒剂的n-杂芳基取代的苯胺衍生物 | |
| GB2548542A (en) | Compounds | |
| CN119095852A (zh) | 含嘧啶酮的17-β-羟基类固醇脱氢酶13型抑制剂 | |
| EP3200796B1 (en) | 4-aminopyrimidine compounds in combination with a chemotherapy agent for treating cancer | |
| BR112019013493B1 (pt) | Compostos heterocíclicos e seus usos, composição farmacêutica e método de mobilização de células-tronco hematopoiéticas e células progenitoras endoteliais na circulação periférica | |
| HK40010586A (en) | Heterocyclic compounds and use thereof | |
| JPH04210667A (ja) | 免疫抑制剤としてのフェニルアセトニトリルアルキルアミノアルキルーオルトー置換アリール化合物 | |
| WO2023224128A1 (ja) | 線維症の治療又は予防のための医薬組成物 | |
| NZ754272B2 (en) | Heterocyclic compounds and use thereof | |
| HK1240496A1 (en) | 4-aminopyrimidine compounds in combination with a chemotherapy agent for treating cancer | |
| HK1240496B (en) | 4-aminopyrimidine compounds in combination with a chemotherapy agent for treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201127 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201127 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20201127 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20201215 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210105 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210325 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210406 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210430 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20210604 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210604 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210908 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6982716 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |